APIS-Ibiyobyabwenge Peptide GLP-1 Semaglutide

Ibisobanuro bigufi:

Semaglutide ni analogue nshya ya GLP-1 (glucagon isa na peptide -1) yakozwe na NovoNordisk, isosiyete yo muri Danemark.Semaglutide nuburyo bukoreshwa bwa dosiye ndende ishingiye kumiterere shingiro ya liraglutide, igira ingaruka nziza mukuvura diyabete yo mu bwoko bwa 2.Semaglutide igira ingaruka nziza mubice byinshi byingenzi, harimo pancreas, umutima numwijima.

Ohereza imeri kuri twe

Ibicuruzwa birambuye

Ibicuruzwa

Ibyerekeye Iki kintu

Semaglutide birashoboka ko GLP-1 ikora neza.
Kugeza ubu, ibiyobyabwenge byingenzi bigabanya ibiro ku isoko birimo orlistat yo muri Roche, liraglutide yo muri Novo Nordisk na semaglutide.

Wegovy, analogue ya GLP-1 ya Novo Nordisk, yemejwe na FDA mu 2017 kuvura diyabete yo mu bwoko bwa 2.Muri kamena 2021, FDA yemeje ibimenyetso byerekana Wegovy.

Mu 2022, umwaka wambere wubucuruzi wuzuye nyuma yurutonde rwa Wegovy, Wegovy yungutse miliyoni 877 zamadorali yerekana kugabanya ibiro.

Hamwe nurutonde rwa semaglutide, ubuyobozi bwubutaka rimwe mubyumweru bwateje imbere cyane kubahiriza abarwayi, kandi ingaruka zo kugabanya ibiro ziragaragara.Ingaruka zo kugabanya ibiro mubyumweru 68 ziri hejuru ya 12.5% kurenza iyo muri placebo (14.9% vs 2,4%), kandi yabaye ibicuruzwa byinyenyeri mumasoko yo kugabanya ibiro mugihe runaka.

Mu gihembwe cya mbere cya 2023, Wegovy yinjije miliyoni 670 z'amadolari y'Amerika, yiyongeraho 225% umwaka ushize.

Kwemeza kugabanya ibiro byerekana semaglutide bishingiye cyane cyane ku cyiciro cya III cyiswe INTAMBWE.STEP ubushakashatsi isuzuma cyane cyane ingaruka zo kuvura inshinge zo mu bwoko bwa semaglutide 2.4mg rimwe mu cyumweru ugereranije na placebo ku barwayi bafite umubyibuho ukabije.

Ibicuruzwa bidahwitse

Kuki Duhitamo

Ubushakashatsi bwa STEP bwarimo ibigeragezo bitari bike, aho hashakishijwe abarwayi bakuze bafite ibiro birenze 4500 cyangwa babyibushye, harimo:
INTAMBWE 1 ubushakashatsi (bufashijwe nubuzima bwubuzima) bwagereranije umutekano wibyumweru 68 nubushobozi bwo gutera inshinge ziterwa na semaglutide 2.4mg rimwe mubyumweru hamwe na placebo muri 1961 bafite umubyibuho ukabije cyangwa ufite ibiro byinshi.

Ibisubizo byerekanye ko impuzandengo yuburemere bwumubiri yari 14.9% mumatsinda ya semaglutide na 2,4% mumatsinda ya PBO.Ugereranije na PBO, ingaruka za gastrointestinal ziterwa na semaglutide zirasanzwe, ariko inyinshi murizo zigihe gito kandi zirashobora kugabanuka nta guhagarika burundu gahunda yo kuvura cyangwa bigatuma abarwayi bava mubushakashatsi.Ubushakashatsi bwa STEP1 bwerekana ko semaglutide igira ingaruka nziza zo kugabanya ibiro kubarwayi bafite umubyibuho ukabije.

INTAMBWE 2 (abarwayi bafite umubyibuho ukabije barwaye diyabete yo mu bwoko bwa 2) bagereranije umutekano n’akamaro ko gutera inshinge za semaglutide 2,4 mg rimwe mu cyumweru hamwe na placebo na semaglutide 1.0mg mu bantu 1210 bafite umubyibuho ukabije cyangwa ufite ibiro byinshi mu byumweru 68.

Ibisubizo byerekanye ko impuzandengo yuburemere bwumubiri wamatsinda atatu yo kuvura yahindutse cyane, hamwe -9,6% mugihe ukoresheje mg 2,4 ya semaglutide, -7% mugihe ukoresheje 1.0mg ya semaglutide, na -3.4% mugihe ukoresheje PBO.Ubushakashatsi bwa STEP2 bwerekana ko semaglutide yerekana kandi ingaruka nziza zo kugabanya ibiro kubarwayi bafite umubyibuho ukabije wa diyabete yo mu bwoko bwa 2.

INTAMBWE 3 ubushakashatsi (adjuvant intensive imyitwarire yubuvuzi) bwagereranije itandukaniro ryibyumweru 68 mumutekano no gukora neza hagati yo guterwa insimburangingo ya semaglutide 2,4 mg rimwe mubyumweru hamwe na placebo ihujwe nubuvuzi bukomeye bwimyitwarire kubantu 611 bafite umubyibuho ukabije cyangwa ufite ibiro byinshi.
Mu byumweru 8 byambere byubushakashatsi, amasomo yose yakiriye indyo yuzuye yo gusimbuza indyo yuzuye ya Calorie hamwe nubuvuzi bukomeye bwimyitwarire muri gahunda y'ibyumweru 68.Abitabiriye amahugurwa basabwa kandi gukora iminota 100 yimyitozo ngororamubiri buri cyumweru, hiyongeraho iminota 25 buri byumweru bine kandi ntarengwa niminota 200 buri cyumweru.

Ibisubizo byerekanye ko uburemere bwumubiri w’abarwayi bavuwe na semaglutide hamwe n’ubuvuzi bukomeye bwagabanutseho 16% ugereranije n’ibanze, mu gihe itsinda rya placebo ryagabanutseho 5.7%.Duhereye ku makuru ya STEP3, dushobora kubona ingaruka zimyitozo ngororamubiri nimirire mugutakaza ibiro, ariko igishimishije, gushimangira imibereho bisa nkaho bidafite ingaruka nke mugukomeza ingaruka zibiyobyabwenge bya semaglutide.

Ikigereranyo gitandukanye

(Kugereranya igipimo cyo kugabanya ibiro hagati yitsinda rya Semaglutide nitsinda rya Dulaglutide)

Umuti urashobora kongera glucose metabolisme utera pancreatic β selile gusohora insuline;Kandi ubuze uturemangingo twa alpha pancreatic selile gusohora glucagon, bityo bigabanye kwiyiriza ubusa hamwe nisukari yamaraso nyuma yinyuma.

(Kugereranya uburemere bwumubiri hagati ya Semaglutide yo kuvura hamwe na placebo)

Ugereranije na placebo, Semaglutide irashobora kugabanya ibyago byingenzi byanyuma (urupfu rwa mbere rwumutima nimiyoboro y'amaraso, infarction myocardial infatal infonction, stroke idapfa) 26%.Nyuma yimyaka 2 yo kuvurwa, Semaglutide irashobora kugabanya cyane ibyago byo guhitanwa nubwonko bwica 39%, infirasiyo ya myocardial idapfa na 26% naho urupfu rwumutima nimiyoboro 2%.Byongeye kandi, irashobora kandi kugabanya gufata ibiryo igabanya ubushake bwo kurya no kugabanya igogorwa ryigifu, kandi amaherezo igabanya ibinure byumubiri, bifasha kugabanya ibiro.

Muri ubu bushakashatsi, byagaragaye ko phentermine-topiramate na GLP-1 reseptor agonist byagaragaye ko ariwo muti mwiza wo kugabanya ibiro mu bantu bakuru bafite umubyibuho ukabije.

Mbere:

Ibikurikira: Catalog peptide ELAMIPRETIDE / SS-31 / MTP-131 / RX-31 Cardiolipin peroxidase inhibitor